A single dose trial of mizagliflozin for the treatment of postbariatric hypoglycemia
Abstract
Abstract Context Postbariatric hypoglycemia (PBH) is a complication of bariatric surgery characterized by severe postprandial hypoglycemia for which there is no approved therapy. Objective To evaluate efficacy and safety of mizagliflozin, a sodium glucose cotransporter 1 inhibitor, for treatment of PBH. Methods This was a phase 2, open-label, randomized, single-dose, crossover study. Nine participants with PBH were randomized to receive a baseline mixed meal tolerance test (MMTT), and single doses of mizagliflozin before each of 2 additional MMTTs. Doses included a 2.5-mg liquid formulation, and 2.5-, 5-, and 10-mg capsules. The primary outcome was change from baseline in glucose nadir, and the main secondary outcomes were change from baseline peak glucose and peak insulin. Results Compared to baseline, all individual doses of mizagliflozin raised the glucose nadir: 6.2 mg/dL (2.5-mg capsule), 17.5 md/dL (2.5-mg liquid), 4.0 mg/dL (5-mg capsule) and 31.5 mg/dL (10-mg capsule). In a post hoc analysis of participants that exhibited hypoglycemia (<70 mg/dL) during the baseline MMTT, mizagliflozin (all capsule doses combined) raised the glucose nadir by 38% (P = .03). Treatment with mizagliflozin also lowered both peak glucose by 21% (P = .03) and peak insulin by 53% (P = .016). Glucose-dependent insulinotropic peptide area under the curve0-3h was reduced by 45% from baseline (P = .048). Conclusion Mizagliflozin resulted in improved glucose nadir, reduction in both postprandial…
How strong is the evidence?
Evidence Hub reads this as a randomized trial. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.